title: [Efficacy of erlotinib on advanced non-small cell lung cancer].
abstract: OBJECTIVE
  Erlotinib is a selective inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase, and has been used in treating advanced non-small cell lung cancer (NSCLC). This study was to evaluate the efficacy of erlotinib on advanced NSCLC, and observe the adverse events.
  
  
  METHODS
  An open labeled, expanded access program (EAP) was conducted on 44 pathologically confirmed advanced NSCLC patients who had received at least one regimen. Erlotinib (150 mg) was orally administered daily till disease progression or intolerable adverse events developed. The efficacy was evaluated according to RECIS criteria; the adverse events were evaluated according to NCI criteria.
  
  
  RESULTS
  In the 44 patients, the objective response rate was 27.3%, and the disease control rate was 65.9%û the median progression-free survival time was 4.5 months (0.9-8.1 months), and the median survival time was 13.7 months (9.2-18.2 months). Adverse events were generally mild (grade I or II), including skin rash (81.8%) and diarrhea (56.8%). One (2.3%) patient developed grade III elevation of serum glutamate pyruvate transaminase (SGPT). No grade IV drug-related adverse event occurred.
  
  
  CONCLUSIONS
  Erlotinib is effective and safe for locally advanced or metastatic NSCLC patients who have failed previous chemotherapy.
authors.affiliation: State Key Laboratory of Oncology in South China, Guangzhou, Guangdong, 510060, PR China.
authors.forename: Hong-Yun
authors.initials: HY
authors.lastname: Zhao
authors.forename: Yang
authors.initials: Y
authors.lastname: Zhang
authors.forename: He
authors.initials: H
authors.lastname: Huang
authors.forename: Li-Kun
authors.initials: LK
authors.lastname: Chen
authors.forename: Guang-Chuan
authors.initials: GC
authors.lastname: Xu
authors.forename: Li
authors.initials: L
authors.lastname: Zhang
mesh_terms: D000328:Adult; D000368:Aged; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000401:mortality; D018572:Disease-Free Survival; D066246:ErbB Receptors / Q000235:genetics; D000069347:Erlotinib Hydrochloride; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D011799:Quinazolines / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D011799:Quinazolines; D000069347:Erlotinib Hydrochloride; D066246:ErbB Receptors